Optimal duration of androgen deprivation in combination with radiation therapy for japanese men with high-risk prostate cancer

Urologia Internationalis

Volumn 87, Issue 1, 2011, Pages 28-34

  Takaha, Natsuki ^a   Okihara, Koji ^a   Kamoi, Kazumi ^a   Kimura, Yasunori ^a   Yamada, Takeshi ^a   Kawauchi, Akihiro ^a   Kobayashi, Kana ^a   Yamazaki, Hideya ^a   Nishimura, Tsunehiko ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Androgen deprivation therapy; Biochemical progression; External beam radiation therapy; High risk group; Prostate cancer

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GYNECOMASTIA; HEMATURIA; HIGH RISK PATIENT; HUMAN; JAPANESE; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION INJURY; RECTUM HEMORRHAGE; SIDE EFFECT; TREATMENT DURATION; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051788342     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000324478     Document Type: Article

References (20)

1. Crawford ED: Epidemiology of prostate cancer. Urology 2003; 62: 3-12. (Pubitemid 38050194)
2. Ajiki W, Tsukuma H, Oshima A: Cancer incidence and incidence rates in Japan in 1999: Estimates based on data from 11 populationbased cancer registries. Jpn J Clin Oncol 2004; 34: 352-356. (Pubitemid 43115318)
3. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
5. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
6. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW: Sixmonth androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827. (Pubitemid 39079668)
7. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. (Pubitemid 32727802)
8. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M: Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002; 54: 1302-1310. (Pubitemid 35380028)
9. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946. (Pubitemid 32184600)
10. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-106.
11. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): An open randomised phase III trial. Lancet 2009; 373: 301-308.
12. Milecki P, Kwias Z, Martenka DJ: Radiotherapy combined with hormonal therapy (RTHT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: Perspective and therapeutic gain analysis. Neoplasma 2007; 54: 7-15.
13. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR: Treatment of patients with high risk localized prostate cancer: Results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol 2005; 173: 1557-1561. (Pubitemid 40528444)
14. Yoshioka Y, Suzuki O, Kobayashi K, Teshima T, Yamada Y, Kotsuma T, Koizumi M, Kagawa K, Chatani M, Shimamoto S, Tanaka E, Yamazaki H, Inoue T: External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: Time trends, outcome, and risk stratification. Strahlenther Onkol 2009; 185: 446-452.
15. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003; 21: 3972-3978. (Pubitemid 46606211)
16. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M: Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193. (Pubitemid 43907319)
17. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H: Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-Cap. Jpn J Clin Oncol 2007; 37: 775-781. (Pubitemid 350120301)
18. Meng MV, Carroll PR: Treatment of locally advanced prostate cancer; in Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds): Campbell-Walsh Urology. Philadelphia, Saunders, 2007, pp 3063-3065.
19. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504.
20. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527.